GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UroGen Pharma Ltd (LTS:0XOD) » Definitions » Short-Term Capital Lease Obligation

UroGen Pharma (LTS:0XOD) Short-Term Capital Lease Obligation : $0.00 Mil (As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is UroGen Pharma Short-Term Capital Lease Obligation?

UroGen Pharma's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2025 was $0.00 Mil.

UroGen Pharma Short-Term Capital Lease Obligation Historical Data

The historical data trend for UroGen Pharma's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UroGen Pharma Short-Term Capital Lease Obligation Chart

UroGen Pharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Short-Term Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

UroGen Pharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Short-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

UroGen Pharma Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

UroGen Pharma Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of UroGen Pharma's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

UroGen Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UroGen Pharma Ltd (LTS:0XOD) » Definitions » Short-Term Capital Lease Obligation
Comparable Companies
YMAB CRGX SLS CDXS TNGX INBX OMER CRDF TLSA ACTU VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
URGN:USA UR8:Germany
Address
400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540
Website
https://www.urogen.com
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

UroGen Pharma Headlines

No Headlines